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Abstract
Blood pressure (BP) control in hypertensive patients remains poor worldwide, particularly in high-risk patients with 
hypertension and diabetes.
New ESH/ESC guidelines recommend more stringent BP targets (on-treatment values of ≤ 130/80 mm Hg in the 
general population and ≤ 140/90 mm Hg in older hypertensive people), which will make the achievement of BP 
control even more challenging.
The most effective evidence-based treatment strategy to improve BP control is one that: encourages the use of com-
bination treatment, enables the use of single-pill combination (SPC) therapy for most patients to improve adherence 
to treatment, with the use of SPC therapy as initial therapy. 
The combination of perindopril with thiazide-like diuretic indapamide is one of the widely tested SPC in multicentre 
clinical trials for diabetic patients. Studies suggested that two-drug combination therapy will control BP in approxi-
mately two-thirds of patients. For patients whose BP is not controlled by two-drug combination therapy, the logical 
option is to increase treatment to three-drug combination therapy: usually a RAS blocker, a CCB and a diuretic.
The combination of perindopril with indapamide and amlodipine is particularly recommended in population of 
hypertensive patients with metabolic complications because of favourable, neutral effect on blood glucose and 
cholesterol level. This combination has proven hypotensive effect in group of patients with difficult-to-control 
hypertension.
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A new strategy for the treatment 
of hypertension 
Hypertension is currently the most important mortal-
ity risk factor in the world and a major public health 
problem, especially in developed countries. It is esti-
mated that currently there are over one billion people 
living with hypertension worldwide, and by 2025 this 
number is predicted to increase by 60% [1, 2].
Thanks to the advances in antihypertensive drug 
therapy we can effectively lower blood pressure in 
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individual patients and, thereby, reduce the main risk 
factor of cardiovascular (CV) events. Despite this, 
epidemiological studies clearly indicate poor blood 
pressure control in the whole population. The lowest 
rate of adequate control of hypertension is observed 
among patients with diabetes, chronic kidney dis-
ease, stable angina, acute coronary syndrome and left 
ventricular dysfunction [3–5].
The authors of the 2018 European Society of Hy-
pertension/European Society of Cardiology (ESH/ 
/ESC) guidelines emphasize that their main goal was 
to develop a strategy that ensures improved blood 
pressure (BP) control in treated patients. The most 
important elements of this strategy are:
1. Lowering of blood pressure treatment 
targets
According to current guidelines, BP should be low-
ered to less than 140/90 mm Hg in all patients and 
if the treatment is well tolerated, further lowering of 
BP to 130/80 mm Hg or less, but not below 120/70 
mm Hg, is recommended. Target BP values in pa-
tients with grade 2 and 3 hypertension should be 
achieved within 3 months of treatment.
2. Recommendation of a single-pill 
combination for the initiation of treatment in 
the majority of patients
The first step should be two-drug combination the-
rapy, preferably in a single-pill combination. The pre-
ferred two-drug combinations include a renin-angio-
tensin system (RAS) inhibitor with a calcium channel 
blocker or a diuretic. Monotherapy is recommended 
only in low-cardiovascular-risk patients with grade 
1 hypertension, in very-high-risk patients with high 
normal BP, in people over 80 years of age and those 
with frailty syndrome.
3. Recommendation of three-drug 
combination in the second step
If the treatment goal is not achieved with two-drug 
combination therapy, a three-drug combination 
based on a RAS inhibitor, a calcium channel blocker 
(CCB) and a diuretic should be used [6].
Single-pill combinations — an effective 
way to improve the effectiveness 
of treatment
Factors determining insufficient control of blood 
pressure include factors related to the patient (adher-
ence/compliance, knowledge) and factors related to 
the doctor (therapeutic inertia).
A common problem that contributes to insuf-
ficient BP control worldwide is poor patient adher-
ence to dosing schedules and treatment advice. The 
degree to which patients’ behaviour is consistent with 
the prescribed treatment is referred to as adherence 
(or compliance) [7]. Studies assessing patient-doctor 
relations by means of electronic monitoring have 
found that 50–60% of all patients strictly follow 
medical recommendations (referred as ‘adherent’ pa-
tients), 30–40% take at least 80% of the prescribed 
doses (‘partially adherent’ patients), while 5–10% of 
patients take less than 80% of the prescribed doses 
or do not take drugs at all (‘non-adherent’ patients) 
[8, 9]. Adherence to treatment decreases as the num-
ber of pills taken daily increases [10].
The introduction of single-pill combinations was 
helpful in improving antihypertensive effectiveness. 
It has been shown that adherence to treatment can 
be significantly improved by reducing the number 
of pills [11].
It is widely believed that inappropriate doctor’s 
behaviour, including insufficient determination in 
treatment and not using all therapeutic options, is 
also an important source of treatment failure. Thera-
peutic inertia (TI) is defined as failure to intensify 
treatment despite the fact that therapeutic goals are 
not achieved. This problem concerns not only BP 
control, but also other chronic diseases, including 
diabetes and hyperlipidaemia [12–14].
The above phenomenon is observed especially in 
patients with relatively slightly elevated blood pres-
sure. The problem of therapeutic inertia was eval-
uated in an American, retrospective cohort study 
involving 7253 hypertensive patients treated in 62 
medical practices. The TI index was calculated for 
each patient, with higher values corresponding to 
higher therapeutic inertia. The main manifestation of 
TI in his study was the failure to increase the dose of 
the antihypertensive drug or to add a new drug even 
though BP values measured during the clinical visit 
were above the target range. The study confirmed 
that the proportion of patients with sufficient blood 
pressure control is lower in ‘real-life’ clinical practice 
than in large clinical trials, and that the incidence of 
TI is high. Another important observation in this 
study was the lack of appropriate action, especially 
in a group of patients at high risk of cardiovascular 
diseases, defined as coexistence of diabetes, heart 
failure or other overt cardiovascular diseases, who 
would benefit the most from appropriate treatment. 
It was estimated that reducing the TI by 50% would 
reduce the average systolic blood pressure by more 
than 5 mm Hg and allow for achieving a BP control 
rate of 65–70%, which is similar to values reported 
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in many clinical trials [15]. Sustained reduction of 
systolic blood pressure by 5 mm Hg for several years 
reduces the risk of major cardiovascular events by 
15–20% [16].
Problems related to hypertension 
in metabolic syndrome and diabetes 
Hypertension is 1.5–2 times more prevalent in dia-
betic patients compared with healthy subjects. The 
coexistence of these two conditions leads to endo-
thelial dysfunction, vascular damage and accelera-
tion of the atherosclerotic process, and consequently 
increases the risk of cardiovascular events [17, 18]. 
It is estimated that CV risk in this group of patients 
is 5 times higher than in those without diabetes and 
without hypertension. Moreover, the presence of hy-
pertension is responsible for a 7.2-fold increase in the 
risk of death in people with diabetes [19, 20].
Metabolic syndrome, often referred to as pre-dia-
betes, is an independent risk factor of cardiovascular 
and cerebral events [21].
In the published studies, the risk of cardiovascu-
lar events was significantly higher among patients 
with metabolic syndrome and remained high even 
after adjusting for age, gender, total cholesterol, cre-
atinine, smoking, left ventricular hypertrophy and 
24-hour systolic blood pressure [21, 22 ].
The pathophysiology of hypertension in diabetes 
and metabolic syndrome is complex. Currently, it is 
believed that the basic pathophysiological mecha-
nism is endothelial dysfunction manifested by va-
soconstriction, increased oxidative stress, vasculitis, 
prothrombotic state, smooth muscle cell prolifera-
tion and impaired repair mechanisms. Along with 
endothelial damage, the renin-angiotensin-aldoste-
rone system is activated as a key modulator of vascu-
lar function [23, 24].
Another important pathophysiological mechanism 
of hypertension in this group of patients is insulin 
resistance which induces the activation of the sympa-
thetic and the renin-angiotensin-aldosterone systems 
and the retention of sodium and water [25, 26].
Selection of optimal treatment 
in the light of the 2018 ESH/ESC 
guidelines
Step one: initiation of antihypertensive  
therapy 
The choice of antihypertensive therapy in patients 
with metabolic syndrome and/or diabetes should be 
made according to current medical standards, select-
ing drugs with antihypertensive efficacy and cardio-
vascular protective effect confirmed in EBM trials.
The current 2018 ESH/ESC guidelines indicate 
the need to lower blood pressure to 130/80 mm Hg 
or less (but not lower than 120/70) within 3 months 
using the first-choice combination of a RAS inhibitor 
with a calcium channel blocker (CCB) or a diuretic, 
preferably in the form of a single-pill combination 
(SPC) [6].
Considering new recommendations and EBM 
approach, the optimal therapy for the initiation of 
antihypertensive treatment in patients with diabetes 
is the combination of perindopril with indapamide. 
As indicated by evidence from clinical trials, this 
treatment ensures a significant reduction in CV 
risk and a reduction in all-cause and cardiovascu-
lar mortality (ADVANCE and ADVANCE-ON) as 
well as a complete normalization of blood pressure 
(PICASSO) and metabolic parameters (FORTIS-
SIMO) [27–30].
The use of individualized combination antihyper-
tensive treatment is supported by the fact that the 
majority of patients with diabetes and hypertension 
do not achieve blood pressure target values. Analysis 
of data from the I-SEARCH (International Survey 
Evaluating Microalbuminuria Routinely by Cardi-
ologists in patients with Hypertension) study showed 
that among diabetic patients only 19% of men and 
in 16% of women had good blood pressure control, 
although 93.5% of patients received antihypertensive 
drugs [31].
In the ADVANCE (Action in Diabetes and Vas-
cular Disease study: PreterAx and DiamicroN Con-
trolled Evaluation) trial including 11,140 patients 
with type 2 diabetes, after 4.3 years of treatment with 
fixed combination of perindopril and indapamide 
statistically significant reduction compared to pla-
cebo was observed in:
 — all-cause mortality [relative risk reduction (RRR) 
14%; p = 0.025];
 — cardiovascular mortality (RRR 18%; p = 0.027);
 — total renal events (RRR 21%; p < 0.0001);
 — total coronary events (RRR 14%; p = 0.02);
 — primary endpoint (total micro- and macroangio-
pathic events) (RRR 9%; p = 0.041).
Treatment with perindopril and indapamide was 
well tolerated; the percentage of adherent patients 
was 73% in the experimental group and 74% in the 
placebo group [27].
All surviving participants of ADVANCE tri-
al were invited to participate in ADVANCE-ON 
(Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Evalu-
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ation Observational Study), both those who were 
treated with perindopril/indapamide and those re-
ceiving placebo. In total, 8494 patients participated 
in the ADVANCE-ON. The median follow-up after 
the end of the randomized trial was 5.9 years, and 
the total duration of the ADVANCE trial and post-
trial follow-up was 9.9 years. The analysis of data 
obtained during nearly 10 years of observation of 
patients with type 2 diabetes, including the period of 
the randomized trial and post-trial follow-up, showed 
a statistically significant reduction in the number of 
deaths from cardiovascular causes and deaths for any 
cause, resulting from previous 4.5-year antihyperten-
sive treatment with perindopril and indapamide. The 
results obtained in the ADVANCE-ON were mainly 
due to sustained benefits of intensive antihyperten-
sive treatment with a fixed combination of perindo-
pril and indapamide in the ADVANCE study [28]. 
This proves that an early and effective reduction in 
blood pressure by fixed combination of perindopril 
and indapamide translates into long-term clinical 
benefits.
It is also worth paying attention to the results of 
the trials assessing the effectiveness of the highest 
doses of the perindopril/indapamide combination 
(PICASSO and FORTISSIMO). In an open ob-
servational PICASSO (Prevention of Cardiovascular 
Events in Ischaemic Stroke Patients with High Risk 
of Cerebral Haemorrhage) trial, the effectiveness of 
fixed-dose combination of perindopril 10 mg/indap-
amide 2.5 mg was evaluated in hypertensive patients 
who failed to achieve BP target values < 140/90 
mm Hg using standard treatment. Blood pressure 
significantly decreased from 158.9 ± 14.3/93.0 ± 
9.4 mm Hg to 131.5 ± 9.5/79.9 ± 6.2 mm Hg. 
Target BP values were achieved by 72.7% of the 
9257 patients included in the final analysis. The 
BP reduction was significant regardless of the initial 
values. Interestingly, significant improvement in the 
metabolic parameters such as total cholesterol, LDL 
and HDL cholesterol, triglycerides and blood glucose 
levels was also observed. The authors conclude that 
treatment with the perindopril 10 mg/indapamide 
2.5 mg combination is effective and safe in patients 
with poorly controlled blood pressure [29]. Simi-
lar conclusions were reached by the authors of the 
FORTISSIMO (Full-dose Perindopril/Indapamide 
in the Treatment of Difficult-to-Control Hyperten-
sion) trial [30].
This combination is also indicated in patients 
with metabolic syndrome, which was confirmed 
by the OPTIMAX study: Real-life Rates of Blood 
Pressure Normalization With First-Line Therapy 
(OPTIMAX 2) [32].
The coexistence of abdominal obesity, dyslipi-
daemia and impaired glucose tolerance is related to 
a very high risk of developing type 2 diabetes and 
cardiovascular diseases.
Patients with metabolic syndrome should be treat-
ed with medications that have additional beneficial 
metabolic effects, beyond lowering blood pressure, 
and delay the development of diabetes [33, 34]. It 
has been known for a long time that the majority 
of antihypertensive drugs affects carbohydrate me-
tabolism. Thiazide diuretics, especially when given in 
high doses, enhance metabolic disorders and increase 
the risk of diabetes. In a prospective multicentre 
TROPHY (Treatment in Obese Patients With Hy-
pertension) trial, obese hypertensive patients were 
randomized to treatment with an ACE inhibitor 
or hydrochlorothiazide (HCTZ). The therapeutic 
goal of lowering the diastolic blood pressure below 
90 mm Hg was obtained by 60% of patients in the 
ACE inhibitor group and only 43% of patients in 
the HCTZ group. In addition, patients receiving 
HCTZ showed significant deterioration of the meta-
bolic profile with significantly higher plasma glucose 
levels and a significant reduction in serum potassium 
compared to the ACE inhibitor group. This study 
emphasized that ACE inhibitors are more advanta-
geous and safer in patients with obesity [35]. At the 
same time, it has been found that HCTZ — not only 
in monotherapy, but also in combination with other 
drugs – unfavourably affects the metabolic profile. 
A subanalysis of the International VErapamil SR 
Trandalapril STUDy (INVEST) published in 2013, 
based on pharmacogenetics, demonstrated that 
the use of HCTZ, even at low doses (12.5 mg and 
25 mg), in combination with an ACE inhibitor may 
be in some patients an environmental factor in the 
development of diabetes. In practice, every 6 months 
of treatment resulted in a 16% increase in the risk of 
developing diabetes [36].
In connection with the above, the guidelines of 
the Polish Society of Hypertension emphasize that 
the preferred diuretics should be thiazide-like diuret-
ics (chlorthalidone, indapamide). This recommenda-
tion is justified by the evidence for their beneficial 
effect on CV risk reduction and a more favourable 
metabolic profile [5].
Differences in the chemical structure of diuret-
ics are the basis for dividing this group of drugs 
into thiazides and thiazide-like diuretics (chlortha-
lidone, indapamide). Different chemical structure 
translates into different pharmacokinetic properties 
and potential additional effects. Unique features of 
indapamide, which are associated with its chemical 
structure, include its considerable lipophilicity, vaso-
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dilating and antioxidant effects and neutral effect on 
the lipid profile.
Due to these beneficial pharmacokinetic proper-
ties, indapamide is now widely used both in mono-
therapy and in single-pill combinations with an ACE 
inhibitor and a CCB. Indapamide is characterized 
by one of the highest trough-to-peak (T/P) ratios 
indicating duration of action of more than 24 hours. 
In a published meta-analysis of 10 randomized trials 
comparing directly indapamide with HCTZ, indap-
amide was shown to have significantly higher antihy-
pertensive efficacy than HCTZ [37].
Another published meta-analysis showed that 
thiazide-like diuretics, including indapamide, sta-
tistically significantly reduce the risk of cardiovascu-
lar events such as stroke, coronary events and heart 
failure. For thiazide diuretics, including HCTZ, the 
reduction of cardiovascular events did not reach sta-
tistical significance [38]. The current guidelines of 
the Polish Society of Hypertension indicate indap-
amide as the preferred thiazide-like diuretic, and in 
some groups of patients (those aged over 80) it is the 
only one recommended [5].
Step two: intensification of treatment 
Based on the research, it is estimated that two-
drug therapy can effectively control BP in nearly 
two thirds of patients [39]. For patients who fail to 
achieve target BP values, the logical option would be 
to use a combination of three antihypertensive drugs. 
A three-drug combination enables achieving the tar-
get BP values in more than 80% of patients [40].
Considering the above, the new 2018 ESH/ESC 
guidelines recommend that the combination of 
a RAS inhibitor, a CCB and a diuretic, preferably 
as a three-drug SPC, should be used for treatment 
intensification [6].
The Polish Society of Hypertension guidelines 
highlight the importance of a new group of three-
drug combinations and indicate the superiority of 
single-pill combination of perindopril/indapamide/
amlodipine [5]. This recommendation is supported 
by EBM studies confirming its effectiveness in re-
ducing CV risk [27, 41, 42]. In addition, this new 
three-drug combination is characterized by 24-hour 
antihypertensive effects of all three drugs which have 
complementary pharmacokinetic properties in terms 
of time required to achieve maximum concentration 
of individual components [43].
Subanalysis of the ADVANCE trial showed sig-
nificantly more favourable effects in patients with 
type 2 diabetes receiving single-pill combination of 
perindopril and indapamide with amlodipine. There 
was a 2-fold reduction in the risk of death compared 
to perindopril/indapamide therapy in the entire pop-
ulation of the ADVANCE trial [44].
In the PIANIST (Perindopril-Indapamide plus 
Amlodipin in high-riSk hyperTensive patients) trial, 
the efficacy of triple combination of perindopril, in-
dapamide and amlodipine was evaluated in patients 
with difficult-to-control blood pressure. One third of 
respondents had ischaemic heart disease or diabetes, 
and half of the subjects had grade 2 hypertension. 
The mean office BP value was 160.5 ± 13.3/93.8 
± 8.7 mm Hg. The target BP values were achieved 
in 72% of all subjects, in 81% of patients previously 
treated with an ACE inhibitor and HCTZ, and in 
91% of patients receiving a sartan and HCTZ prior 
to the study entry. This analysis of treatment effects 
in nearly five thousand patients with high or very 
high cardiovascular risk confirmed the effectiveness 
of the above triple antihypertensive therapy, regard-
less of the type of previously used two-drug combina-
tion [45]. Another study assessing the combination 
of perindopril, indapamide, and amlodipine, PETRA 
(PErindopril based TRiple combination therapy to 
Achieve 24-hours controlled hypertension), included 
over 11,000 patients with grade 1, 2 and 3 hyper-
tension with associated cardiovascular risk factors 
and concomitant diseases (dyslipidaemia, diabetes, 
obesity and coronary heart disease) ). After 3 months 
of treatment with perindopril, indapamide and am-
lodipine, systolic blood pressure decreased by 25 
mm Hg, and diastolic blood pressure by 11 mm Hg. 
In the context of new recommendations, it should 
be emphasized that the above combination made it 
possible to achieve more stringent therapeutic goals 
of <130/80 mm Hg in only 3 months. What’s more, 
45% of patients received the lowest dose of the drug 
(5/1.25/5 mg) on the last visit [46].
Summary 
Hypertensive patients with diabetes or metabolic 
syndrome are characterized by high or very high 
cardiovascular risk. According to the new 2018 ESH/
ESC guidelines, effective prevention of incidents in 
this group of patients requires achieving target BP 
values of systolic blood pressure between 130 and 
120 mm Hg and diastolic blood pressure between 
80 and 70 mm Hg within 3 months. The first step of 
antihypertensive pharmacotherapy should be a two-
drug combination of a RAS inhibitor with a diuretic 
or a CCB, preferably in a SCP. In the second step, 
a combination of three drugs: a RAS inhibitor, a di-
uretic and a CCB, preferably in a SPC, should be 
used in order to intensify the treatment. In accor-
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dance with the current guidelines, respective steps 
for patients with diabetes and metabolic syndrome 
should be as follows: the combination of perindopril/ 
/indapamide as the first step of treatment and three-
drug combination of perindopril/indapamide/amlo-
dipine for treatment intensification. This treatment 
strategy is supported by many EBM trials confirming 
its effectiveness in achieving target BP values and 
organ-protective effects.
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